Clinical trial · Interventional
Radiation Therapy Plus Chemotherapy in Treating Patients With Pancreatic Cancer
Phase II Interstitial Colloidal 32P Integrated in The Treatment of Non-Resectable Pancreatic Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy combined with chemotherapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of brachytherapy followed by external-beam radiation therapy plus chemotherapy in treating patients who have pancreatic cancer that cannot be removed surgically.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (5)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| brachytherapy | Radiation | — | UNRESOLVED |
| dexamethasone | Drug | Dexamethasone | ALIAS |
| fluorouracil | Drug | Fluorouracil | ALIAS |
| phosphorus P32 | Radiation | — | UNRESOLVED |
| radiation therapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (3)
- measure
- Response rate
- measure
- Duration of remission
- measure
- Survival
Secondary outcomes (1)
- measure
- Patterns of failure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically proven unresectable adenocarcinoma of the pancreas limited to the head, body, or tail of the pancreas * Diameter no greater than 5 cm * Volume no greater than 66 mL * No ascites (with or without tumor cells) * No endoscopically proven tumor penetration of duodenum or stomach PATIENT CHARACTERISTICS: Age: * 18 and over Performance status: * Karnofsky 70-100% Hematopoietic: * WBC at least 3,000/mm3 * Platelet count at least 100,000/mm3 * Hemoglobin at least 9 g/dL (transfusion allowed) Hepatic: * No hepatic disease * At least 50% uptake of technetium-sulfur colloid in normal liver if cirrhosis suspected * No vascular occlusion of portal system Renal: * Creatinine no greater than 1.5 mg/dL * BUN no greater than 25 mg/dL Other: * No Crohn's disease, ulcerative colitis, or other inflammatory bowel disease * Not pregnant PRIOR CONCURRENT THERAPY: Biologic therapy: * Not specified Chemotherapy: * If prior chemotherapy, test dose of colloidal phosphorous P32 administered prior to attempted treatment Endocrine therapy: * Not specified Radiotherapy: * No prior radiotherapy to pancreas, liver, or upper gastrointestinal tract Surgery: * No complete surgical resection * No splenectomy
References
Publications (0)
Data not yet available